The GOLDEN model uses pre-treatment qHBsAg kinetics to predict which chronic hepatitis B patients will likely achieve a functional cure when transitioning to combination therapy. If you are on long-term NA treatment, discuss your viral kinetic profile with your doctor to determine if you are a candidate for interferon-based combination therapy.
Learn how the GOLDEN prediction model uses viral kinetics to identify chronic hepatitis B patients most likely to achieve a functional cure through therapy.
A functional cure is the sustained loss of hepatitis B surface antigen (HBsAg) from your blood, often accompanied by the development of protective anti-HBs antibodies. This state indicates that your immune system has gained sufficient control over the virus to suppress it even without ongoing antiviral medication.
The GOLDEN model calculates a predictive index (Pi) based on your historical qHBsAg levels. By analyzing how your antigen levels have changed over time, the model assigns a score that estimates your statistical likelihood of achieving HBsAg clearance if you add pegylated interferon to your current antiviral regimen.
No, pegylated interferon therapy carries significant risks, including severe flu-like symptoms, potential depression, and changes in blood counts. Because of these side effects, it is generally reserved for patients who have a high probability of responding to the treatment, which is why predictive models like GOLDEN are used.
HBsAg loss is a major clinical milestone, but the virus may still persist in the liver in a dormant state known as covalently closed circular DNA (cccDNA). While functional cure is the best achievable outcome with current treatments, long-term monitoring is still required to ensure the virus does not reactivate.